Economic impact of Elantan la compared to Isordil, Tenormin and Tildiem la in the treatment of stable angina in the UK

Abstract

This study estimated the NHS cost of treating stable angina with Elantan LA compared to Isordil, Tenormin and Tildiem LA. Angina-related healthcare resource use from the UK Mediplus database was obtained for new patients, switched patients and existing patients who received one of the four drugs for stable angina and had one of the following Read Codes: history of angina pectoris; history of angina in the last year; angina control; and angina pectoris. Resource use was stratified according to the following comorbidities: ischaemic heart disease (excluding angina); hypertension; congestive cardiac failure; hypercholesterolaemia; and cerebrovascular disease. National resource costs (at 1997/98 prices) were assigned to the resources used, to estimate the cost of each treatment strategy over one year to achieve the same level of clinical effectiveness. © 2000 Informa UK Ltd All rights reserved.